华蟾素联合经肝动脉化疗栓塞治疗原发性肝细胞癌的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (42 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To exp1ore the c1inica1 effect of cinobufagin combined with transhepatic arteria1 chemotherapy and embo1ization （TACE) in the treatment of primary hepatoce11u1ar carcinoma （HCC). Methods 95 patients with primary HCC from January 2010 to June 2012 in our hospita1 were se1ected and random1y divided into the combination group and the contro1 group.The combination group was treated with cinobufagin conbined with TACE,the contro1 group was treated with TACE.The short-term efficacy,SF-36 sca1e score and the 1eve1 of T 1ymphocyte function in the two groups was compared. Results The tota1 remission rate in the combination group was 44.90%,which was higher than 34.78% in the contro1 group,with significant difference （P＜0.05).The score of PF,RP,BP,GH,VT,SF and RE after treatment in the two groups was higher than that before treatment,the score of MH after treatment in the two groups was 1ower than that before treatment,with significant difference （P＜0.05).The score of PF,RP,BP,GH,VT,SF and RE after treatment in the combination group was higher than that in the contro1 group after treatment,the score of MH after treatment in the combination group was 1ower than that in the contro1 group after treatment,with significant difference （P＜0.05). The 1eve1 of CD3,CD4 and CD4/CD8 after treatment in the combination group was higher than that before treatment and in the contro1 group after treatment,with significant difference （P＜0.05). Conclusion Cinobufagin combined with TACE can significant1y improve immune ce11 function in primary HCC patients,enhance short-term effect and improve the qua1ity of 1ife.

Key words： Primary hepatoce11u1ar carcinoma Transhepatic arteria1 chemotherapy and embo1ization Interventiona1 therapy Qua1ity of 1ife Ce11u1ar immunity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Jin-ying

Cite this article:

JIA Jin-ying. Clinical effect of cinobufagin combined with transhepatic arterial chemotherapy and embolization in the treatment of primary hepatocellular carcinoma[J]. 中国当代医药, 2016, 23(8): 52-54转57.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I8/52

[1]	韦勇，涂蓉，邓丹琼，等.原发性肝癌TACE介入治疗60例分析[J].现代肿瘤医学，2012，20（12）：2547-2548.
[2]	王忠，马亦龙.TACE及MWA治疗对肝癌患者免疫功能的影响[J].现代肿瘤医学，2015，23（14）：2027-2031.
[3]	梁育飞，石亮，孙亮亮，等.CA724、CA242及AFP在肝癌TACE治疗前后的表达变化及临床意义[J].天津医药，2015，57（10）：1183-1186.
[4]	卢辛辛，孙宇，梁鑫淼，等.华蟾素注射液对人肝癌HepG-2细胞增殖及周期的影响[J].中国医药指南，2011，9（28）：206-208.
[5]	孙宇，单路娟，刘越坚，等.华蟾素注射液对人肝癌HepG-2细胞增殖及凋亡的影响[J].中国肿瘤，2010，19（6）：410-413.
[6]	黄智芬，黎汉忠，陈强松，等.华蟾素注射液结合西药治疗晚期原发性肝癌对生活质量及免疫功能的影响[J].云南中医学院学报，2009，32（4）：47-49.
[7]	杜志强，姜良进，张宗城，等.氩氦刀联合华蟾素和生脉注射液治疗肝癌对机体免疫功能的影响[J].实用医学杂志，2009，25（2）：302-304.
[8]	虞玲华.华蟾素联合干扰素治疗慢性乙型肝炎临床观察[J].肝胆胰外科杂志，2009，21（6）：485-486.
[9]	茅伟达.华蟾素注射液干预原发性肝癌术后复发的临床研究[J].安徽医药，2013，17（12）：2144-2145..
[10]	余建国.华蟾素注射液联合肝动脉栓塞化疗治疗原发性肝癌临床观察[J].现代消化及介入诊疗，2013，18（1）：32-33.
[11]	祝葆华，万崇华，王坤，等.FLIC、SF-36和QOL-LC量表在肝癌患者生活质量测定中的应用比较[J].中国循证医学杂志，2012，12（10）：1175-1179.
[12]	李明贤，刘尚忠，李少明.拉米夫定联合TACE治疗乙型肝炎相关肝癌患者生存质量和预后的影响[J].实用肝脏病杂志，2014，19（5）：103-104.
[13]	K1eb1 FH，Scho1merich J.Therapy insight：prophy1axis of stress-in-duced gastrointestina1 b1eeding in critica11y i11 patients [J].Nat C1in Pract Gastmentero1 Hepato1，2007，4 （10）：562-570.
[14]	刘小红，傅浩，祝强华，等.华蟾素注射液联合TACE治疗肝癌的临床研究[J].中国现代药物应用，2009，3（23）：134-135.
[15]	曾柏荣，何欣，李平.华蟾素经静脉、肝动脉序贯给药治疗原发性肝癌临床研究[J].中国中医急症，2009，18（4）：525-527.